Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103519 · ClinicalTrials.gov registry record · Phase 2
Study of DITPA in Patients With Congestive Heart Failure
A Phase 2 study, sponsored by Titan Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT00103519 is a Phase 2 study that was terminated before completion, run by Titan Pharmaceuticals. The registered enrollment target is 86 participants.
The verdict
NCT00103519, a Phase 2 study, was terminated before completion, sponsored by Titan Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of DITPA relative to placebo in patients with New York Heart Association (NYHA) class III or IV congestive heart failure (CHF) who have low serum T3. DITPA is an investigational agent.
Interventions
- DRUG Placebo
- DRUG DITPA (3,5-diiodothyropropionic acid)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00103519
The ClinicalTrials.gov registry entry for NCT00103519 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Titan Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00103519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00103519 about?
NCT00103519 is a clinical study titled "Study of DITPA in Patients With Congestive Heart Failure". This study will assess the safety and efficacy of DITPA relative to placebo in patients with New York Heart Association (NYHA) class III or IV congestive heart failure (CHF) who have low serum T3. DITPA is an investigational agent.
What is the current status of trial NCT00103519?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2004-12. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00103519?
The interventions under investigation include: Placebo (DRUG), DITPA (3,5-diiodothyropropionic acid) (DRUG).
Who is sponsoring clinical trial NCT00103519?
This trial is sponsored by Titan Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.